{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-9156052-leuprolide:v1","objectPathId":"pubmed-pmid-9156052-leuprolide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-9156052-leuprolide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-9156052-leuprolide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-9156052-leuprolide-v1.md"},"story":{"slug":"pubmed-pmid-9156052-leuprolide","version":1,"domain":"Literature metadata","dateInSource":"2013-11-21","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["leuprolide"],"peptides":[{"slug":"leuprolide","url":"https://peptidescanner.com/peptides/leuprolide/"}]},"claims":[{"id":"headline","text":"Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?","sourceIds":["pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813"]},{"id":"summary","text":"PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813"]},{"id":"paragraph-1","text":"PubMed lists PMID 9156052 in Clinical endocrinology as Comment, Letter, with publication-date metadata of 1997-03 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813"]}],"sources":[{"id":"pubmed-observation-pmid-9156052-2013-11-21-b51eb4621813","name":"PubMed","sourceClass":"A","title":"Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new? · retained source version 1:2013-11-21:current:b51eb4621813afe7992641f0c673678bed5182ff92e0ff74767c41f0abb1cec9","url":"https://pubmed.ncbi.nlm.nih.gov/9156052/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"1f73af0b3bc55729f930930153e2459fcb6842acf6105e4f556d32752798a513","tierARecordSha256":"7b005c2eda025ef7a00751737203edb952d97629b49b9c364f8c3f7d99ca836b"},"integrity":{"algorithm":"sha256","contentSha256":"8cdc7cf68fe9b20f74d145760eb52d8b0257b6fbe994080f915929f14a327be6"}}